Company research / CVSI

CV Sciences, Inc. (CVSI)

CIK 0001510964 · OTC · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, CV Sciences, Inc. reported revenue of $13.79M. Revenue fell 12.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $12.74M.

Key ratios (year ended 2025-12-31)

49.0%
Gross margin
-3.4%
Operating margin
-6.9%
Net margin
-65.3%
Return on year-end equity
-12.2%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$12.74M$13.79M$15.71M$16.00M$16.20M$20.05M$24.43M$53.70M$48.24M$20.68M$11.06M
Cost of Revenue$6.48M$7.04M$8.54M$8.92M$10.65M$11.43M$13.42M$18.61M$14.37M$6.19M$4.06M
Gross Profit$6.26M$6.75M$7.17M$7.08M$5.55M$8.62M$11.01M$35.09M$33.88M$14.49M$7.00M
R&D Expense$78.0K$122.0K$118.0K$151.0K$307.0K$1.19M$2.94M$5.88M$1.89M$724.0K$1.16M
Operating Income-$969.0K-$470.0K-$2.19M$3.36M-$6.85M-$18.45M-$22.59M-$17.24M$10.25M-$4.86M-$13.07M
Depreciation & Amortization$97.0K$192.0K$334.0K$235.0K$992.0K$1.15M$872.0K$716.0K$519.0K$183.0K$1.05M
EBITDA-$872.0K-$278.0K-$1.86M$3.60M-$5.86M-$17.29M-$21.72M-$16.52M$10.77M-$4.68M-$12.02M
Net Income-$2.01M-$958.0K-$2.39M$3.10M-$8.21M-$15.55M-$22.28M-$16.61M$10.00M-$4.90M-$14.14M
EPS (Diluted)n/a-$0.01-$0.01$0.02-$0.07-$0.14-$0.22-$0.17$0.09-$0.06n/a
Total Assets$6.52M$6.96M$7.93M$9.20M$12.74M$18.07M$30.62M$52.69M$36.90M$22.71M$18.59M
Total Liabilities$4.95M$5.49M$6.13M$6.30M$13.51M$14.52M$19.41M$23.54M$6.79M$6.33M$5.38M
Long-Term Debtn/a$1.65Mn/an/an/an/an/an/an/an/an/a
Shareholders' Equity$1.57M$1.47M$1.79M$2.90M-$777.0K$3.54M$11.21M$29.15M$30.12M$16.38M$13.21M
Cash & Equivalentsn/an/an/an/a$611.0K$1.38M$4.02M$9.11M$12.68Mn/an/a
Operating Cash Flow-$492.0K-$407.0K-$861.0K$2.25M-$1.89M-$7.49M-$7.30M-$2.23M$12.56M$3.62M-$2.05M
Capital Expenditures$30.0K$109.0K$18.0K$0$0$35.0K$1.06M$1.15M$893.0K$454.0K$17.2K
Free Cash Flow-$522.0K-$516.0K-$879.0K$2.25M-$1.89M-$7.52M-$8.36M-$3.37M$11.67M$3.16M-$2.07M
Shares Outstanding213.12M184.26M184.26M161.68M152.10M112.48M100.66M99.42M94.94M90.51M57.62M
Weighted Average Diluted Sharesn/a184.26M175.59M153.96M138.03M107.82M99.91M97.86M114.47M80.43Mn/a
EPS (Basic)n/a-$0.01-$0.01$0.02-$0.07-$0.14-$0.22-$0.17$0.11-$0.06n/a